89bio Reports First Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/13/20
89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial and Reports New Preclinical Data Confirming BIO89-100’s Mechanism of Action Via Potent FGF Receptor AgonismGlobeNewsWire • 04/13/20
89bio Appoints Healthcare Industry Veteran Steven Altschuler, M.D., as Chairman of the Board of DirectorsGlobeNewsWire • 03/25/20